Barely Significant
← all excerpts

CSCO expert consensus on the diagnosis and treatment of breast cancer brain metastasis.

Transl Breast Cancer Res · 2022 · PMC11092996 · PMID 38751521

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

showed a trendno p-value reported
In the phase III trial CLEOPATRA, the combination with pertuzumab delayed the median time to development of CNS metastases at the first site of disease progression ( 84 ); in the PHEREXA study, the addition of pertuzumab to trastuzumab and capecitabine showed a trend in PFS benefit ( 85 ); in a single-arm, prospective, phase II study, however, patients with HER2-positive metastatic breast cancer with BMs and CNS progression despite prior radiotherapy received pertuzumab plus high-dose trastuzumab (6 mg/kg weekly), and the CNS-ORR was only 11%, showing a non-significant result ( 67 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.